BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:12 PM
 | 
Nov 18, 2009
 |  BC Extra  |  Clinical News

Epiphany's valomaciclovir meets Phase IIb endpoint

Epiphany Biosciences Inc. (San Francisco, Calif.) said the two highest doses (2 and 3 g) of once-daily valomaciclovir ( EPB-348) met the primary...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >